Can Establishment Labs shift the breast reconstruction standard in the U.S. with Motiva?
Find out how Establishment Labs is aiming to transform U.S. breast reconstruction with Motiva implants and FDA approval. Read what changes and risks lie ahead.
Genmab ends acasunlimab trials: What it signals about bispecific immunotherapy risk
Genmab ends development of acasunlimab to focus on EPKINLY, petosemtamab, and Rina-S. Find out what this shift means for 4-1BB bispecifics today.
Can PathoCare’s $1.75bn tender offer reprice the future of AI-driven diagnostics?
Find out why PathoCare’s $1.75B valuation and expanded $50M financing round could signal a breakthrough moment for AI-powered point-of-care diagnostics.
Why Verastem Oncology’s KRAS G12C trial exit reveals a calculated pivot to next-generation lung cancer targets
Verastem exits its G12C lung cancer trial to prioritize VS-7375, a next-gen G12D inhibitor showing promise. Find out how this pivot could change KRAS therapy.
Vicarious Surgical bets on outsourced software execution to control costs and advance clinical timelines
Vicarious Surgical shifts software development to a global partner to cut costs and hit clinical trial milestones. Here’s what this means for its platform.
Can subcutaneous infusion disrupt oncology workflows? Inside KORU Medical’s 510(k) strategy for FreedomEDGE
KORU Medical’s 510(k) filing for FreedomEDGE with PHESGO could reshape subcutaneous cancer therapy. Find out what this means for oncology care delivery.
NeoImmuneTech takes over Endari’s U.S. rights from Emmaus: What this signals for the future of sickle cell treatment
NeoImmuneTech takes over U.S. rights for Endari from Emmaus Life Sciences. Find out what this deal reveals about the future of sickle cell treatment.
Delcath subgroup data links survival to tumor burden and LDH in uveal melanoma
New Phase 3 subgroup data suggest Delcath’s HEPZATO KIT improves survival in patients with lower tumor burden or LDH. Learn what this means for mUM treatment.
How Sanofi’s CpG 1018 platform could reshape vaccine formulation in 2026
Sanofi’s acquisition of CpG 1018 brings TLR9 adjuvants to the forefront. Explore how this could transform combo vaccines and adult immunization strategies.
From Parkinson’s to platform scalability: What’s next for Sinopia’s LEADS technology
Sinopia Biosciences receives NIH grant to expand its LEADS platform. Find out how AI and metabolomics could transform drug discovery.